Mauna Kea wins 510(k) for new urinary tract probes; Synergetics improves finances through more contract manufacturing;

@FierceMedDev: Quotient, a UK diagnostics outfit, filed plans for a $75M IPO. Via Renaissance Capital. Brief | Follow @FierceMedDev

@MarkHFierce: The European Patent Office tossed out an Edwards heart valve patent--a big victory for rival Medtronic. More | Follow @MarkHFierce

@MichaelGFierce: Study: In two-drug, HIV-preventing vaginal ring, only one drug does the job. Piece | Follow @MichaelGFierce

@EmilyWFierce: Stapler-sized device could identify disease biomarkers and insulin levels, all in one read. Story via RTT News | Follow @EmilyWFierce

@GalenMoore: Last year's M&A darling, Biomet files for an IPO. It's said to be looking for a $1B raise. News | Follow @GalenMoore

> France's Mauna Kea Technologies gained a 510(k) clearance to cover the use of its Cellvizio technology to probe the urethra, bladder and ureter by way of an endoscope or related accessories. Item 

> Medical device manufacturer Synergetics ($SURG)  boosted net sales and reduced net losses in its recently-concluded second quarter, thanks to strong gains in its contract manufacturing business. Item

> The Gores Group and Technology4Medicine in metro-Los Angeles have snatched up Fotona, a Slovenia operation that manufactures medical lasers. Story

> The BioMaryland Center handed out $1.5 million in awards to Johns Hopkins and 7 biotech companies for projects including the development of a device that would lessen some risks involved with cardiac ablation. Item

> The Medical Imaging and Technology Alliance is pursuing a new campaign to educate policymakers about how medical imaging improves healthcare and can lower costs. Item

Biotech News

@FierceBiotech: After 2 years trailing Boston, San Francisco rules our list of the top 15 cities for biotech VC. Report | Follow @FierceBiotech

@JohnCFierce: And continuing to run strong from Wednesday, which is unusual--FDA rejects Eli Lilly's SGLT2 diabetes drug empagliflozin. Story | Follow @JohnCFierce

@DamianFierce: New Link's cancer vaccine brings hopeful investors back down to earth. More | Follow @DamianFierce

@EmilyMFierce: Stem cell therapy developed by International Stem Cell Corp. improves Parkinsons symptoms in monkeys. Story | Follow @EmilyMFierce

> GlaxoSmithKline's FDA batting average tops the industry; Lilly, not so much. Article

> A Phase III win puts Incyte's cancer drug in line for blockbuster status. Piece

Pharma News

@FiercePharma: And the best-read special report, our newest: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: ICYMI: It's trial by fire for Zogenix, as painkiller Zohydro's launch meets public furor. News | Follow @TracyStaton

@EricPFierce: Novartis has more skin in the dermatology game with EU approval of Xolair to treat chronic hives. Story | Follow @EricPFierce

@CarlyHFierce: Working on a new report... looks like it's time to add "write extensive Advair pieces off the top of my head" to my list of party tricks. | Follow @CarlyHFierce

> Pfizer recalls 104,000 bottles of antidepressant Effexor XR. Story

> Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year. Article

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.